Oncotartisincis A Private Biotechnology Company Established In 2011It Is Located At The Thomas Rbeecher Innovation Center On Buffalo Niagara Medical Campusit Has A Strategic Partnership With Roswell Park Cancer Institute Where The Original Intellectual Property Was Developed In The Laboratory Of Professor Andrei Gudkov Missionto Revolutionize Treatment Of A Subset Of Cancersbreastprostateovarianmelanoma And Hematological Malignanciesby Developing A Novel Category Of Anti Cancer Drugs Directed Against Tissuespecific Targets Technologyoncotartis Is Exploring A Proprietary Drug Discovery Approach Calledtartis Tartis = Targeting Tissue Tartis Is Designed To Develop Small Molecules For Treatment Of Malignancies Originating From Specific Tissues That Are Either Non Essential For The General Viability Of Mammalian Organismi E Gender Associated Tissues Or Melanocytesor Can Be Effectively Replacedhematopoietic Systemleading Candidatean Anti Aml Candidateot 82Has A Favorable Set Of Structuraladme And Toxicological Propertiesa Broad Composition Of Matter Patent Applicationwas Filed In 2013Ot 82 Is An Namptnicotinamide Phosphoribosyl Transferaseinhibitora Remarkably Broad Spectrum Of Nampt Functions Positions Ot 82 As A Drug Candidate For Treatment Of Other Nampt Dependent Cancersinflammatory Diseases And Disorders Associated With Deregulated Circadian Clock
No conferences found for this company.
| Company Name | Oncotartis Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
